John L Villano

20PUBLICATIONS
53CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsCancer geneticsRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Feb 11, 2026
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors.

John L Villano, Jason J Luke, Ricklie Julian

|Jun 20, 2025
Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma.

John L Villano, Catherine R Garcia, Rachael M Morgan

|Jan 25, 2025
Outcomes of Brain Metastasis from Lung Cancer.

James M Mobley, Kerry I Phillips, Quan Chen

|Jan 18, 2025
Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing.

Alexia Shamaei Zadeh, Danielle Roberts, Abby Williams

|Sep 12, 2024
A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.

Olivier Rixe, John L Villano, Robert Wesolowski

|Aug 10, 2024
Glioblastoma Standard of Care: Effects on Tumor Evolution and Reverse Translation in Preclinical Models.

Louis T Rodgers, John L Villano, Anika M S Hartz

Pageof 4